

This listing of claims replaces all prior versions and listings of claims in this application.

LISTING OF CLAIMS:

Claim 1 (Currently Amended): A tablet prepared by direct compression of ~~comprising~~ crystals of a pharmaceutically acceptable salt of citalopram and pharmaceutically acceptable excipients, wherein the median particle size of the crystals is at least 40 μm , ~~which is prepared by direct compression of the pharmaceutically acceptable salt and pharmaceutically acceptable excipients.~~

Claims 2-3 (Canceled).

Claim 4 (Previously Presented): The tablet according to claim 1 which does not contain a binder.

Claim 5 (Previously Presented): The tablet according to claim 1 which contains 2-60% w/w active ingredient calculated as citalopram base.

Claim 6 (Previously Presented): The tablet according to claim 1 which contains a filler selected from lactose, sugars, calcium phosphates, starch, modified starches, microcrystalline cellulose, calcium sulfate and calcium carbonate.

{W:\05432\000I004-000\00082756.DOC [XXXXXXXXXXXXXXXXXXXX] }

Claim 7 (Previously Presented): The tablet according to claim 6, wherein the filler is a microcrystalline cellulose.

Claim 8 (Previously Presented): The tablet according to claim 1 which contains a lubricant selected from metallic stearates, stearic acid, wax, hydrogenated vegetable oil, talc and colloidal silica.

Claim 9 (Previously Presented): The tablet according to claim 8, wherein the lubricant is magnesium stearate or calcium stearate.

Claim 10 (Previously Presented): The tablet according to claim 1 which is substantially free of lactose.

Claim 12 (Previously Presented): The tablet according to claim 1 wherein the pharmaceutically acceptable salt is citalopram hydrobromide or citalopram hydrochloride.

Claim 13 (Previously Presented): The tablet according to claim 12, wherein the pharmaceutically acceptable salt is citalopram hydrobromide.

Claims 14-35 (Canceled).

Claim 36 (Previously Presented): The tablet of claim 1, which contains 10-40% w/w active ingredient calculated as citalopram base.

{W:\05432\000I004-000\00082756.DOC [REDACTED]}

Claim 37 (Previously Presented): The tablet of claim 1, which contains 15-25% w/w active ingredient calculated as citalopram base.

Claim 38 (Previously Presented): The tablet of claim 6, wherein said filler is a sugar selected from the group consisting of sorbitol, mannitol, dextrose and sucrose.

Claim 39 (Previously Presented): The tablet of claim 6, wherein said filler is a calcium phosphate selected from the group consisting of dibasic, tribasic, hydrous and anhydrous calcium phosphate.

Claim 40 (Previously Presented): The tablet of claim 8, wherein said lubricant is a metallic stearate selected from the group consisting of magnesium, calcium and sodium stearate.

Claim 41 (Previously Presented): The tablet of claim 1, wherein the crystals have a median particle size of 40-200 μm .

Claim 42 (Previously Presented): The tablet of claim 1, wherein the crystals have a median particle size of 45-150 μm .

Claim 43 (Previously Presented): The tablet of claim 1, wherein the crystals have a median particle size of 50-100 μm .

{W:\05432\000I004-000\00082756.DOC }

Claims 44-92 (Canceled).

{W:\05432\000I004-000\00082756.DOC [REDACTED]}